SCHEMBL2479367

SCHEMBL2479367

NNc1ccnc(C(F)(F)F)c1

nearest known ligand 0.54

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LOXL2 Q9Y4K0 2/20 0.52
SMARCA2 P51531 1/20 0.51
SMARCA4 P51532 1/20 0.51
LOX P28300 1/20 0.50
TAS2R14 Q9NYV8 1/20 0.43
NOTUM Q6P988 1/20 0.40
HDAC4 P56524 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
IDO1 P14902 1/20 0.40
CA2 P00918 1/20 0.39
CHKA P35790 1/20 0.39
IDH1 O75874 2/20 0.39
IDH2 P48735 2/20 0.39
SYK P43405 1/20 0.39
NOS3 P29474 1/20 0.38
NOS2 P35228 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30505955 1.00 LOXL2 (0.52) LOXL2SMARCA2SMARCA4LOXTAS2R14
Hydrochloric Acid SCHEMBL31696645 0.98 LOXL2 (0.53) LOXL2SMARCA2SMARCA4LOXTAS2R14
Hydrochloric Acid SCHEMBL16633226 0.98 LOXL2 (0.53) LOXL2SMARCA2SMARCA4LOXTAS2R14
SCHEMBL9234478 0.80 SMARCA2 (0.51) LOXL2SMARCA2SMARCA4LOXTAS2R14
SCHEMBL11523071 0.80 SMARCA2 (0.41) LOXL2SMARCA2SMARCA4LOXIDO1
SCHEMBL23639222 0.80 SMARCA2 (0.51) LOXL2SMARCA2SMARCA4LOXTAS2R14
SCHEMBL30016319 0.80 SMARCA2 (0.51) LOXL2SMARCA2SMARCA4LOXTAS2R14
SCHEMBL15992647 0.77 SMARCA2 (0.64) LOXL2SMARCA2SMARCA4HDAC4HDAC6
SCHEMBL30595621 0.77 SMARCA2 (0.64) LOXL2SMARCA2SMARCA4HDAC4HDAC6
SCHEMBL2443384 0.76 SMARCA2 (0.51) LOXL2SMARCA2SMARCA4LOXTAS2R14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630533-B2 Heterocyclic compounds useful as KCNT1 inhibitors ACTIO BIOSCIENCES, INC. (US) 2026-05-19 US disclosed
US-20250313548-A1 HETEROCYCLIC COMPOUNDS USEFUL AS KCNT1 INHIBITORS ACTIO BIOSCIENCES, INC. 2025-10-09 US disclosed
CN-116375683-A Diazole derivative inhibitor, preparation method and application thereof 上海翰森生物医药科技有限公司 2023-07-04 CN disclosed
EP-3699179-A1 PYRAZOLYL-CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (CN) 2020-08-26 EP disclosed
EP-2373641-B1 PYRIDAZINONE DERIVATIVES HOFFMANN LA ROCHE (CH) 2012-12-19 EP disclosed
US-8178538-B2 Pyridazinones HOFFMANN-LA ROCHE INC. (US) 2012-05-15 US disclosed
EP-2373641-A1 PYRIDAZINONE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2011-10-12 EP disclosed
US-20100152193-A1 PYRIDAZINONES HOFFMANN-LA ROCHE, INC. 2010-06-17 US disclosed
WO-2010063610-A1 PYRIDAZINONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250313548-A1 HETEROCYCLIC COMPOUNDS USEFUL AS KCNT1 INHIBITORS KCNT1, KCNT2, KCNN3 LOXL2 3755/4885SMARCA2 3978/4885SMARCA4 3571/4885
US-12630533-B2 Heterocyclic compounds useful as KCNT1 inhibitors KCNT1, KCNT2, KCNJ2 LOXL2 2853/4885SMARCA2 3403/4885SMARCA4 3498/4885
US-20100152193-A1 PYRIDAZINONES PDE5A, PDE3A, PDE10A LOXL2 3573/4885SMARCA2 3435/4885SMARCA4 2877/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.